| Dr Nicholas Stephen Milligan, MD | |
|
2693 Forest Hills Road Suite B, Wilson, NC 27893-1355 | |
| (252) 234-2841 | |
| Not Available |
| Full Name | Dr Nicholas Stephen Milligan |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 2693 Forest Hills Road Suite B, Wilson, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114332731 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 2022-01136 (North Carolina) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 2022-01136 (North Carolina) | Primary |
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.
Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-R- and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment.
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
"On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement" under which "$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized," the Devex "Development Newswire" reports.
› Verified 7 days ago
| Entity Name | Atlantic Pathology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356301725 PECOS PAC ID: 0547277246 Enrollment ID: O20060321000134 |
News Archive
Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.
Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-R- and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment.
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
"On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement" under which "$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized," the Devex "Development Newswire" reports.
› Verified 7 days ago
| Entity Name | App-ecp, Llc |
|---|---|
| Entity Type | Part B Supplier - Independent Clinical Laboratory |
| Entity Identifiers | NPI Number: 1578708368 PECOS PAC ID: 6608933221 Enrollment ID: O20090326000402 |
News Archive
Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.
Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-R- and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment.
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
"On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement" under which "$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized," the Devex "Development Newswire" reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas Stephen Milligan, MD 2693 Forest Hills Road Sw Ste. B, Wilson, NC 27893-8611 Ph: (252) 234-2841 | Dr Nicholas Stephen Milligan, MD 2693 Forest Hills Road Suite B, Wilson, NC 27893-1355 Ph: (252) 234-2841 |
News Archive
Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.
Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-R- and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment.
The U.S. Food and Drug Administration today filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company's president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus, and Ebola.
"On Wednesday, the World Bank and the Bangladeshi government signed a Multi-Donor Trust Fund Grant Agreement" under which "$280 million coming from the United States, Australia, the United Kingdom, and Sweden will go to the Bangladesh Health Sector Development Program, which aims to improve the health status of people in Bangladesh, particularly women, children and the marginalized," the Devex "Development Newswire" reports.
› Verified 7 days ago
Dr. Darlene Cheryl Thorne, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1705 Tarboro St Sw, Wilson, NC 27893 Phone: 252-399-8156 | |
George Drennan Smith Ii, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2693 Forest Hills Rd Sw, Suite B, Wilson, NC 27893 Phone: 252-234-2841 | |
Dr. Benjamin Lee Coulter, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2693 Forest Hills Rd Sw, Suite B, Wilson, NC 27893 Phone: 252-234-2841 Fax: 252-234-9270 | |
Dr. Willis Edward Lewis, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1705 Tarboro St Sw, Wilson, NC 27893 Phone: 252-399-8156 | |
Dr. Peter J Kragel, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2693 Forest Hills Rd Sw Ste B, Wilson, NC 27893 Phone: 252-234-2841 | |
Dr. Veena H Doshi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 2693 Forest Hills Rd Sw Ste B, Wilson, NC 27893 Phone: 252-234-2841 Fax: 252-234-9270 |